Welcome to our dedicated page for Ucb S A news (Ticker: UCBJY), a resource for investors and traders seeking the latest updates and insights on Ucb S A stock.
UCB SA reports news as a global biopharmaceutical company focused on severe diseases of the immune system and central nervous system. Updates commonly cover BIMZELX® (bimekizumab-bkzx), an approved medicine designed to selectively inhibit IL-17A and IL-17F, including data and awareness activity in hidradenitis suppurativa and moderate-to-severe plaque psoriasis.
Company announcements also address UCB's epilepsy and rare disease work, including FINTEPLA® (fenfluramine), developmental and epileptic encephalopathies such as Dravet syndrome, Lennox-Gastaut syndrome and CDKL5 deficiency disorder, TK2 deficiency research, patient-support initiatives, and biologics manufacturing capacity.
UCB has published Phase 3 study results demonstrating VIMPAT® (lacosamide) as an effective adjunctive therapy for uncontrolled primary generalized tonic-clonic seizures (PGTCS) in patients with idiopathic generalized epilepsy (IGE). The study, involving 242 patients, found a significant reduction in the risk of experiencing a second PGTCS (HR 0.540; p<0.001) and improved seizure freedom rates (31.3% vs 17.2%, p=0.011) compared to placebo. VIMPAT is currently not approved for this indication, but regulatory reviews are ongoing in the U.S., EU, Japan, and Australia.